ClinicalTrials.gg
RecruitingNCT05583773SHINE-HFUpdated Nov 5, 2026

SHengXIaN-QuYu DEcoction in Heart Failure With Reduced and Mildly Reduced Ejection Fraction

A Phase 4 interventional study of ShengXian-QuYu Decoction and Placebo in Heart Failure, sponsored by China-Japan Friendship Hospital. Recruiting at 26 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by China-Japan Friendship Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.
Updated Nov 5, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.

Planned enrollment
66th of 247
336 · median 130
Started
2023
with 42 others
Phase 4
30 of 377
12 open now
Primary completion
2027-03
later than 103 of 181 live
Registered
184th of 377
by date

Among the 377 studies in Heart Failure with a site in China, this one is the 66th largest by planned enrollment of the 247 interventional ones that give a count, is one of 43 that started in 2023, is one of 30 in phase 4, reaches primary completion later than 103 of the 181 other live ones, and was the 184th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to conduct a multicenter, randomized clinical trial to evaluate the effect of "ShengXian-QuYu Decoction" on quality of life , symptoms, and biomarkers in heart failure patients with reduced and mildly reduced ejection fraction.

Read the detailed description

This is a pragmatic, nationwide, multicenter, parallel group, randomized, double-blind, placebo-controlled study in patients with heart failure with reduced and mildly ejection fraction, evaluating the effect of "ShengXian-QuYu Decoction" versus placebo, given twice daily in addition to background regional standard of care. The effect of "ShengXian-QuYu Decoction"on quality of life, symptoms and biomarkers will be evaluated.

The primary and secondary endpoints will be examined in subgroups determined by baseline variables reflecting demography, heart failure characteristics, Traditional Chinese Medicine syndrome type, diabetes status, kidney function, left ventricular ejection fraction, natriuretic peptide, and additional co-morbidities, concomitant medications, and others.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • ShengXian-QuYu Decoction
  • Heart failure with reduced ejection fraction
  • Heart failure with mildly reduced ejection fraction
  • Quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged ≥18 years at the time of consent.
  2. Established documented diagnosis of symptomatic HFrEF ( functional class II-IV).
  3. \<50%.
  4. NT-proBNP >600 pg/ml or BNP ≥150 pg/ml (or if hospitalized for heart failure within the previous 12 months, NT-proBNP ≥400 pg/ml or BNP ≥100 pg/ml) at enrolment.
  5. Provision of signed prior to any study specific procedures.

Exclusion criteria

Exclusion Criteria:

  1. Current acute decompensated HF or hospitalization due to decompensated HF, ACS, stroke or (TIA), coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]) or valvular repair/replacement, or other major cardiovascular surgery within 4 weeks prior to enrolment.
  2. Uncontrolled severe arrhythmia.
  3. Planned to undergo heart transplantation or device implantation.
  4. Hepatic impairment [AST] or alanine transaminase [ALT] >3x the [ULN]; or total >2x ULN at time of enrolment).
  5. Severe infection.
  6. \<30 mL/min/1.73 m\^2 by CKD-EPI.
  7. Active requiring treatment at the time of visit 1.
  8. Women of who are not willing to use a medically accepted method of that is considered reliable in the judgment of the investigator OR women who have a positive pregnancy test at enrolment or randomization OR women who are breast-feeding.
  9. Any condition outside the CV and renal disease area, such as but not limited to malignancy, with a of less than 1 years based on investigator's clinical judgement.
  10. Systolic blood pressure \< 90 mmHg, or systolic blood pressure ≥ 180 mmHg, or diastolic blood pressure ≥ 110 mmHg on 2 consecutive measurements.
  11. Heart failure due to infiltrative cardiomyopathies(cardiac amyloidosis, etc.), fulminant myocarditis, constrictive pericarditis.
  12. Participation in another clinical study.
  13. Inability of the patient, in the opinion of the investigator, to understand and/or comply with study medications, procedures and/or follow-up OR any conditions that, in the opinion of the investigator, may render the patient unable to complete the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
336 participants (estimated)

Study arms

  • Active comparator
    ShengXian-QuYu Decoction

    Patients will be randomized 1:1 to either ShengXian-QuYu Decoction or placebo. "ShengXian-QuYu Decoction" (calculated by a medicine): 30g of Astragalus membranaceus (Huangqi), 12g of Cornus officinalis (Shanzhuyu), 9g of Panax ginseng (Hongshen), 12g of Anemarrhena asphodeloides (Zhimu), 8g of Cimicifuga foetida (Shengma), 8g of Bupleurum chinense (Chaihu), 10g of Platycodon grandiflorum (Jiegeng), 10g of Sparganium stoloniferum (Sanleng), 9g of Curcuma phaeocaulis (Ezhu), 3g of Whitmania pigra (Shuizhi).

    Drug: ShengXian-QuYu Decoction

  • Placebo comparator
    placebo

    Placebo matching ShengXian-QuYu Decoction

    Other: Placebo

Interventions

  • DrugShengXian-QuYu Decoction

    Specification: 30ml/bag, given twice daily, per oral use.

  • OtherPlacebo

    Placebo matching ShengXian-QuYu Decoction, 30ml/bag, given twice daily, per oral use.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the KCCQ Clinical Summary Score

    KCCQ was a 23-item, self-administered questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status. KCCQ-clinical summary score was average of domains- physical limitation and total symptoms (average of symptom frequency and symptom burden), and transformed to a single score which ranged from 0 (worst) -100 (the best possible status), where the higher score reflected better health status.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Change From Baseline in the Traditional Chinese Medicine Syndrome Score Scale (TCMSSS)

    Traditional Chinese Medicine Syndrome Score is a instrument that quantifies symptoms. Lower TCM scores reflect better health status.

    Time frame: Up to 12 weeks

  2. Change in Exercise Capacity as Measured by the 6-Minutes-Walking-Test (6MWT) Distance

    Change from baseline to week 12 in exercise capacity as measured by the distance walked in 6 minutes in standardised conditions. Change from baseline was defined as the distance walked in 6 minutes at week 12 minus the baseline value. Baseline value was defined as the last available measurement before start of treatment with randomised study medication.

    Time frame: Up to 12 weeks

  3. Change in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)

    Change from baseline to week 12 in N-terminal pro-brain natriuretic peptide (NT-proBNP). Baseline value was defined as the mean of all available measurements from the screening visit until start of treatment with randomised study medication.

    Time frame: Up to 12 weeks

  4. Change in Left Ventricular Systolic Function

    Change in left ventricular ejection fraction is assessed by two-dimensional directed M-mode echocardiography.

    Time frame: Up to 12 weeks

  5. Change in Left Ventricular End-Diastolic Diameter

    Change in left ventricular end-diastolic diameter is assessed by two-dimensional directed M-mode echocardiography.

    Time frame: Up to 12 weeks

  6. Change in Left Ventricular End-Systolic Diameter

    Change in left ventricular end-systolic diameter is assessed by two-dimensional directed M-mode echocardiography.

    Time frame: Up to 12 weeks

  7. Change in Estimated Glomerular Filtration Rate from Baseline

    Estimated glomerular filtration rate (eGFR) is calculated by the CKD-EPI equation.

    Time frame: Up to 12 weeks

  8. Change From Baseline in the KCCQ Clinical Summary Score

    KCCQ was a 23-item, self-administered questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status. KCCQ-clinical summary score was average of domains- physical limitation and total symptoms (average of symptom frequency and symptom burden), and transformed to a single score which ranged from 0 (worst) -100 (the best possible status), where the higher score reflected better health status.

    Time frame: Up to 26 weeks

  9. Change From Baseline in the Traditional Chinese Medicine Syndrome Score Scale (TCMSSS)

    Traditional Chinese Medicine Syndrome Score is a instrument that quantifies symptoms. Lower TCM scores reflect better health status.

    Time frame: Up to 26 weeks

Other outcomes

  1. Subjects Included in the Composite Endpoint of Cardiovascular Death and Worsening Heart Failure

    The composite CV endpoint is defined as cardiovascular death, hospitalization due to heart failure or urgent visit required intravenous treatment due to heart failure.

    Time frame: Up to 12 weeks

  2. Subjects Included in the Composite Endpoint of Cardiovascular Death and Worsening Heart Failure

    The composite CV endpoint is defined as cardiovascular death, hospitalization due to heart failure or urgent visit required intravenous treatment due to heart failure.

    Time frame: Up to 26 weeks

  3. Renal Composite Endpoint

    The renal composite endpoint included composite of doubling of serum creatinine (DoSC), end-stage kidney disease (ESKD), and renal death. DoSC: from the baseline average determination (sustained and confirmed by repeat central laboratory measure after at least 30 days and preferably within 60 days). ESKD: initiation of maintenance dialysis for at least 30 days, or renal transplantation, or an eGFR value of \<15 mL/min/1.73 m\^2 (sustained and confirmed by repeat central laboratory measure after at least 30 days and preferably within 60 days). Renal death: death in participants who have reached ESKD, died without initiating renal replacement therapy, and no other cause of death was determined via adjudication. Adjudication of these events by the EAC was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of the renal composite endpoint are presented.

    Time frame: Up to 12 weeks

  4. Renal Composite Endpoint

    The renal composite endpoint included composite of doubling of serum creatinine (DoSC), end-stage kidney disease (ESKD), and renal death. DoSC: from the baseline average determination (sustained and confirmed by repeat central laboratory measure after at least 30 days and preferably within 60 days). ESKD: initiation of maintenance dialysis for at least 30 days, or renal transplantation, or an eGFR value of \<15 mL/min/1.73 m\^2 (sustained and confirmed by repeat central laboratory measure after at least 30 days and preferably within 60 days). Renal death: death in participants who have reached ESKD, died without initiating renal replacement therapy, and no other cause of death was determined via adjudication. Adjudication of these events by the EAC was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of the renal composite endpoint are presented.

    Time frame: Up to 26 weeks

  5. Liver Injury

    Liver injury is defined as: i) a rise of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) to 3 times above the upper limit of normal \[ULN\], or ii) a rise of total bilirubin to 2 times above the upper limit of normal \[ULN\].

    Time frame: Up to 12 weeks

  6. Liver Injury

    Liver injury is defined as: i) a rise of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) to 3 times above the upper limit of normal \[ULN\], or ii) a rise of total bilirubin to 2 times above the upper limit of normal \[ULN\].

    Time frame: Up to 26 weeks

  7. Bleeding Events

    All bleeding events, including major bleeding, non-major clinically relevant bleeding and minimal bleeding (for incidences only) will be assessed.

    Time frame: Up to 12 weeks

  8. Bleeding Events

    All bleeding events, including major bleeding, non-major clinically relevant bleeding and minimal bleeding (for incidences only) will be assessed.

    Time frame: Up to 26 weeks

07

Study locations

26 of 26 sites recruiting
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality 100029, China
    Recruiting
    • Jiang Liu · Contactyzliujiang@163.com · +86 19800361320
    • Jingyi Ren · Principal investigator
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
    Recruiting
  • Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine
    Beijing, Beijing Municipality 100072, China
    Recruiting
    • Lingling Liu · Contact329419791@qq.com · +86 18801200210
    • Lingling Liu · Principal investigator
  • Dongcheng District First People's Hospital
    Beijing, Beijing Municipality 100077, China
    Recruiting
    • Hongyu Fu · Contact66232066@qq.com · +86 13260171971
    • Hongyu Fu · Principal investigator
  • Dongfang Hospital Affiliated to Beijing University of Chinese Medicine
    Beijing, Beijing Municipality 100078, China
    Recruiting
    • Xiaoyun Cui · Contactyou6171@126.com · +86 13811890290
    • Xiaoyun Cui · Principal investigator
  • Huairou District Traditional Chinese Medicine Hospital of Beijing
    Beijing, Beijing Municipality 101400, China
    Recruiting
    • Shaojun Chen · Contact18910842603@163.com · +86 13552301395
    • Shaojun Chen · Principal investigator
  • Beijing Changping Nankou Hospital
    Beijing, Beijing Municipality 102202, China
    Recruiting
    • Liling Zheng · Contact66232066@qq.com · +86 13260171971
    • Liling Zheng · Principal investigator
  • Changping District Traditional Chinese Medicine Hospital
    Beijing, Beijing Municipality 102208, China
    Recruiting
    • Zhao Jin · Contactsingledouya@163.com · +86 13426113311
    • Zhao Jin · Principal investigator
  • Tang County Hospital of Traditional Chinese Medicine
    Baoding, Hebei 072350, China
    Recruiting
    • Jianfei Guan · Contact75821843@qq.com · +86 13483208655
    • Jianfei Guan · Principal investigator
  • Funing Hospital of Traditional Chinese Medicine
    Qinhuangdao, Hebei 066399, China
    Recruiting
    • Shi Li · Contact358743873@qq.com · +86 13001422602
    • Shi Li · Principal investigator
  • Gongyi City Public Hospital of TCM
    Gongyi, Henan 451200, China
    Recruiting
    • Jijie Wang · Contact393190024@qq.com · +86 13838199975‬
    • Feijiao Huo · Principal investigator
  • Yangzhou Hospital of Traditional Chinese Medicine
    Yangzhou, Jiangsu 225127, China
    Recruiting
    • Xiaobin Wang · Contact2336905303@qq.com · +86 18061178158
    • Xiaobin Wang · Principal investigator
  • Jining Hospital of Traditional Chinese Medicine
    Jining, Shandong 272004, China
    Recruiting
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266071, China
    Recruiting
    • Hui Xin · Contactxinhuiqy@163.com · +86 18661801287
    • Hui Xin · Principal investigator
  • The Affiliated Hospital of Changzhi Institute of Traditional Chinese Medicine
    Changzhi, Shanxi 046000, China
    Recruiting
    • Haijun Song · Contact1549916295@qq.com · +86 15534566561
    • Haijun Song · Principal investigator
  • Changzhi Medical College Affiliated Heji Hospital
    Changzhi, Shanxi 046011, China
    Recruiting
    • Xiaojian Liu · Contact787875739@qq.com · +86 18035590665
    • Xiaojian Liu · Principal investigator
  • Changzhi Hospital of Traditional Chinese Medicine
    Changzhi, Shanxi 046099, China
    Recruiting
  • Chengdu Integrated TCM and Western Medicine Hospital
    Chengdu, Sichuan 610095, China
    Recruiting
    • Yao Liu · Contact152101920@qq.com · +86 18011390008
    • Yao Liu · Principal investigator
  • Jixian Chinese Traditional Hospital
    Tianjin, Tianjin Municipality 301900, China
    Recruiting
    • Baolong Yang · Contact176121179@qq.com · +86 13752702312
    • Baolong Yang · Principal investigator
  • Urumqi Hospital of Traditional Chinese Medicine
    Ürümqi, Xinjiang 830000, China
    Recruiting
    • Palidan Wubu'er · Contact767829146@163.com · +86 13999838082
    • Palidan Wubu'er · Principal investigator
  • Changji Hospital of Traditional Chinese Medicine
    Changji, Xinjiang Uygur Autonomous Region 831199, China
    Recruiting
    • Liang Gui · Contactxjguiliang@163.com · +86 13999559026
    • Liang Gui · Principal investigator
  • Korla Hospital of Traditional Chinese Medicine
    Korla, Xinjiang Uygur Autonomous Region 841009, China
    Recruiting
    • Huiyun Li · Contact623966191@qq.com · +86 13999014088
    • Huiyun Li · Principal investigator
  • Xinyuan Traditional Chinese Medicine Hospital
    Xinyuan, Xinjiang Uygur Autonomous Region 835899, China
    Recruiting
    • Weisheng Mao · Contact2717492525@qq.com · +86 18935772083
    • Weisheng Mao · Principal investigator
  • Gulja Hospital of Traditional Chinese Medicine
    Yining, Xinjiang Uygur Autonomous Region 835199, China
    Recruiting
    • Zhiyang Zhang · Contact985104516@qq.com · +86 13999576733
    • Zhiying Zhang · Principal investigator
  • Zhaosu Hospital of Traditional Chinese Medicine
    Zhaosu, Xinjiang Uygur Autonomous Region 835699, China
    Recruiting
    • Chao Zhang · Contact1554306702@qq.com · +86 15739035725
    • Chao Zhang · Principal investigator
  • Linhai Hospital of Traditional Chinese Medicine
    Linhai, Zhejiang 317000, China
    Recruiting
    • Yingjing Song · Contacthyysyj@126.com · +86 13646769521
    • Yingjing Song · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2027, 48 months after the start.

Of 165 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's planned 48 months is above that.

Counting every sponsor, half of 184 studies reached it within 31 months; a quarter within 21 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Aug 2025 → Mar 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2022
First posted
Oct 18, 2022
StartActual
Mar 29, 2023
Primary completionEst.
Mar 31, 2027was Aug 2025
CompletionEst.
Dec 31, 2027was Dec 2025
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
15 sites added, 15 sites removed
Show 15 added (15 China)
  • China-Japan Friendship Hospital · Beijing, China
  • Peking University People's Hospital · Beijing, China
  • Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine · Beijing, China
  • Dongcheng District First People's Hospital · Beijing, China
  • Dongfang Hospital Affiliated to Beijing University of Chinese Medicine · Beijing, China
  • Huairou District Traditional Chinese Medicine Hospital of Beijing · Beijing, China
  • Beijing Changping Nankou Hospital · Beijing, China
  • Changping District Traditional Chinese Medicine Hospital · Beijing, China
  • Jixian Chinese Traditional Hospital · Tianjin, China
  • Urumqi Hospital of Traditional Chinese Medicine · Ürümqi, China
  • Changji Hospital of Traditional Chinese Medicine · Changji, China
  • Korla Hospital of Traditional Chinese Medicine · Korla, China
  • Xinyuan Traditional Chinese Medicine Hospital · Xinyuan, China
  • Gulja Hospital of Traditional Chinese Medicine · Yining, China
  • Zhaosu Hospital of Traditional Chinese Medicine · Zhaosu, China
Show 15 removed
  • China-Japan Friendship Hospital · Beijing, China
  • Peking University People's Hospital · Beijing, China
  • Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine · Beijing, China
  • Dongcheng District First People's Hospital · Beijing, China
  • Dongfang Hospital Affiliated to Beijing University of Chinese Medicine · Beijing, China
  • Huairou District Traditional Chinese Medicine Hospital of Beijing · Beijing, China
  • Beijing Changping Nankou Hospital · Beijing, China
  • Changping District Traditional Chinese Medicine Hospital · Beijing, China
  • Jixian Chinese Traditional Hospital · Tianjin, China
  • Korla Hospital of Traditional Chinese Medicine · Bayan Gol Autonomous Prefecture, China
  • Changji Hospital of Traditional Chinese Medicine · Changji Hui Autonomous Prefecture, China
  • Gulja Hospital of Traditional Chinese Medicine · Ili Kazakh Autonomous Prefecture, China
  • Zhaosu Hospital of Traditional Chinese Medicine · Ili Kazakh Autonomous Prefecture, China
  • Xinyuan Traditional Chinese Medicine Hospital · Ili Kazakh Autonomous Prefecture, China
  • Urumqi Hospital of Traditional Chinese Medicine · Urumqi, China
Nov 5, 2026
Primary completion
Aug 31, 2025→Mar 31, 2027
Nov 5, 2026
Study completion
Dec 31, 2025→Dec 31, 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    15 sites added, 15 sites removed
    Show 15 added (15 China)
    • China-Japan Friendship Hospital · Beijing, China
    • Peking University People's Hospital · Beijing, China
    • Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine · Beijing, China
    • Dongcheng District First People's Hospital · Beijing, China
    • Dongfang Hospital Affiliated to Beijing University of Chinese Medicine · Beijing, China
    • Huairou District Traditional Chinese Medicine Hospital of Beijing · Beijing, China
    • Beijing Changping Nankou Hospital · Beijing, China
    • Changping District Traditional Chinese Medicine Hospital · Beijing, China
    • Jixian Chinese Traditional Hospital · Tianjin, China
    • Urumqi Hospital of Traditional Chinese Medicine · Ürümqi, China
    • Changji Hospital of Traditional Chinese Medicine · Changji, China
    • Korla Hospital of Traditional Chinese Medicine · Korla, China
    • Xinyuan Traditional Chinese Medicine Hospital · Xinyuan, China
    • Gulja Hospital of Traditional Chinese Medicine · Yining, China
    • Zhaosu Hospital of Traditional Chinese Medicine · Zhaosu, China
    Show 15 removed
    • China-Japan Friendship Hospital · Beijing, China
    • Peking University People's Hospital · Beijing, China
    • Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine · Beijing, China
    • Dongcheng District First People's Hospital · Beijing, China
    • Dongfang Hospital Affiliated to Beijing University of Chinese Medicine · Beijing, China
    • Huairou District Traditional Chinese Medicine Hospital of Beijing · Beijing, China
    • Beijing Changping Nankou Hospital · Beijing, China
    • Changping District Traditional Chinese Medicine Hospital · Beijing, China
    • Jixian Chinese Traditional Hospital · Tianjin, China
    • Korla Hospital of Traditional Chinese Medicine · Bayan Gol Autonomous Prefecture, China
    • Changji Hospital of Traditional Chinese Medicine · Changji Hui Autonomous Prefecture, China
    • Gulja Hospital of Traditional Chinese Medicine · Ili Kazakh Autonomous Prefecture, China
    • Zhaosu Hospital of Traditional Chinese Medicine · Ili Kazakh Autonomous Prefecture, China
    • Xinyuan Traditional Chinese Medicine Hospital · Ili Kazakh Autonomous Prefecture, China
    • Urumqi Hospital of Traditional Chinese Medicine · Urumqi, China
    Primary completion Aug 31, 2025→Mar 31, 2027
    Study completion Dec 31, 2025→Dec 31, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05583773
Responsible party
Jingyi Ren (Professor, China-Japan Friendship Hospital) — Principal investigator
First posted
Oct 18, 2022
Start date
Mar 29, 2023
Primary completion
Mar 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Mengxi Yang, Dr.
Contact
mxtezuka@163.com
+86 15120049452
Jiang Liu, Dr.
Contact
yzliujiang@163.com
+86 19800361320

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion